We are live on ! Find out more
ROSG

Rosetta Genomics Ltd.
ROSG

Delisted

ROSG was delisted on the 21st of May, 2018.

16 hedge funds and large institutions have $887K invested in Rosetta Genomics Ltd. in 2014 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

14% more funds holding

Funds holding: 1416 (+2)

46% less capital invested

Capital invested by funds: $1.65M → $887K (-$758K)

50% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 6

87% less call options, than puts

Call options by funds: $5K | Put options by funds: $39K

Holders
16
Holders Change
+2
Holders Change %
+14.29%
% of All Funds
0.43%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
5
Increased
3
Reduced
6
Closed
2
Calls
$5K
Puts
$39K
Net Calls
-$34K
Net Calls Change
+$183K

ROSG Hedge Fund Activity: Q4 2014 in Review

16 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Rosetta Genomics Ltd. (ROSG) for Q4 2014, worth a combined $887K — down 46% from $1.65M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new ROSG positions and 2 closed out — a net gain of 3 holders — while 3 added to existing stakes and 6 trimmed.

The largest buyer was A.R.T. Advisors, opening a new position worth an estimated $44.6K. The largest seller was Wells Fargo, cutting an estimated $363K.

  • 16 institutional investors held Rosetta Genomics Ltd. (ROSG) as of Q4 2014, up from 14 in Q3 2014.
  • Funds reported $887K of Rosetta Genomics Ltd. stock for Q4 2014, down 46% quarter-over-quarter.
  • 5 funds opened new Rosetta Genomics Ltd. positions in Q4 2014 and 2 closed out, a net change of +3 holders.
  • The largest Rosetta Genomics Ltd. buyer in Q4 2014 was A.R.T. Advisors, an estimated $44.6K added.
  • The largest Rosetta Genomics Ltd. seller in Q4 2014 was Wells Fargo, an estimated $363K sold.

Based on aggregated 13F filings for Q4 2014.